Ricardo Rojas-GarcÃ-a

List of Publications by Year
in descending order

72 papers	4,064 citations	147801 31 h-index	128289 60 g-index
79 all docs	79 docs citations	79 times ranked	5454 citing authors

#	Article	IF	Citations
1	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	30
2	Motor neuron involvement expands the neuropathological phenotype of lateâ€onset ataxia in RFC1 mutation (CANVAS). Brain Pathology, 2022, 32, e13051.	4.1	9
3	Drugâ€refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology, 2022, 9, 122-131.	3.7	13
4	Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	15
5	Serum neurofilament light chain predicts long-term prognosis in Guillain-BarrÃ© syndrome patients. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 70-77.	1.9	40
6	A new de novo SYT2 mutation presenting as distal weakness. Neuropathy or neuromuscular junction dysfunction?. Journal of the Peripheral Nervous System, 2021, 26, 113-117.	3.1	5
7	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. Brain Pathology, 2021, 31, e12942.	4.1	9
8	Clinical characteristics and outcomes of thymomaâ€associated myasthenia gravis. European Journal of Neurology, 2021, 28, 2083-2091.	3.3	39
9	Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2021, 144, 1183-1196.	7.6	46
10	Late onset Sandhoff disease presenting with lower motor neuron disease and stuttering. Neuromuscular Disorders, 2021, 31, 769-772.	0.6	6
11	Distal hereditary motor neuropathies: Mutation spectrum and genotypeâ€“phenotype correlation. European Journal of Neurology, 2021, 28, 1334-1343.	3.3	39
12	Autoantibody screening in Guillainâ€“BarrÃ© syndrome. Journal of Neuroinflammation, 2021, 18, 251.	7.2	19
13	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	2.4	6
14	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
15	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	54
16	Genotypeâ€“phenotype correlations in recessive titinopathies. Genetics in Medicine, 2020, 22, 2029-2040.	2.4	35
17	Cortical microstructure in the amyotrophic lateral sclerosisâ€“frontotemporal dementia continuum. Neurology, 2020, 95, e2565-e2576.	1.1	19
18	Transcriptome characterization of the motor cortex suggests microglialâ€related key events due to TDPâ€43 aberrant inclusions. Alzheimer's and Dementia, 2020, 16, e042953.	0.8	0

#	Article	IF	Citations
19	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Scientific Reports, 2020, 10, 4308.	3.3	26
20	Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology, 2020, 94, e1171-e1180.	1.1	88
21	Thrombospondin-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
22	Antibodies against nodo-paranodal proteins are not present in genetic neuropathies. Neurology, 2020, 95, e427-e433.	1.1	11
23	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	3.7	44
24	Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 74-84.	3.0	43
25	Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. Scientific Reports, 2019, 9, 6155.	3.3	20
26	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	7.6	45
27	Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 2019, 14, e0212647.	2.5	2
28	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	3.7	13
29	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	4.4	11
30	Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 576-585.	1.9	38
31	Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies. Annals of Clinical and Translational Neurology, 2018, 5, 559-569.	3.7	18
32	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	1.9	44
33	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0
34	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.1	59
35	Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 964-972.	1.7	5
36	Denervation-activated STAT3â€“IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis. Nature Cell Biology, 2018, 20, 917-927.	10.3	189

#	Article	IF	Citations
37	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 703-709.	1.7	18
38	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
39	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	1.5	4
40	Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 333-340.	1.7	17
41	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
42	Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Scientific Reports, 2017, 7, 14411.	3.3	62
43	Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nature Reviews Neurology, 2017, 13, 533-547.	10.1	188
44	RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Research and Therapy, 2017, 19, 174.	3.5	34
45	Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurology, 2016, 73, 1099.	9.0	90
46	ALS: A bucket of genes, environment, metabolism and unknown ingredients. Progress in Neurobiology, 2016, 142, 104-129.	5.7	158
47	Amyotrophic lateral sclerosis: A higher than expected incidence in people over 80 years of age. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 522-527.	1.7	15
48	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
49	Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. Journal of Neuroimmunology, 2016, 291, 82-88.	2.3	59
50	Transthyretin-related hereditary amyloid polyneuropathy presenting with large fibre involvement and cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 64-65.	3.0	1
51	Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes. Neuromuscular Disorders, 2016, 26, 33-40.	0.6	40
52	Analysis of theCHCHD10gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	7.6	56
53	Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e149.	6.0	205
54	Severe exacerbation of Andersenâ€“Tawil syndrome secondary to thyrotoxicosis. Journal of Human Genetics, 2014, 59, 465-466.	2.3	3

#	Article	IF	Citations
55	Cortactin autoantibodies in myasthenia gravis. Autoimmunity Reviews, 2014, 13, 1003-1007.	5.8	93
56	Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology, 2014, 82, 879-886.	1.1	285
57	Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients. PLoS ONE, 2014, 9, e91927.	2.5	35
58	Paraproteinemic neuropathies. Presse Medicale, 2013, 42, e225-e234.	1.9	8
59	Analysis of theC9orf72Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide. Human Mutation, 2013, 34, 79-82.	2.5	85
60	Comprehensive Care of Amyotrophic Lateral Sclerosis Patients: A Care Model. Archivos De Bronconeumologia, 2013, 49, 529-533.	0.8	11
61	Antibodies to contactinâ€1 in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology, 2013, 73, 370-380.	5.3	279
62	Amyotrophic lateral sclerosis in Catalonia: A population based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 278-283.	1.7	42
63	No evidence for a large difference in ALS frequency in populations of African and European origin: A population based study in inner city London. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 66-68.	2.1	13
64	Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies. Journal of the Peripheral Nervous System, 2012, 17, 158-168.	3.1	15
65	Pachymeningitis, Painful Ophthalmoplegia, and Multiple Cranial Neuropathy of Presumed Tuberculous Origin. Neuro-Ophthalmology, 2011, 35, 289-292.	1.0	1
66	Bulbar involvement in patients with antiganglioside antibodies against NeuNAc(Â2-3)Gal. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 623-628.	1.9	10
67	Antibodies against disialosyl and terminal NeuNAc(Î±2-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy. Journal of Neurology, 2008, 255, 764-766.	3.6	13
68	Chronic sensorimotor polyradiculopathy with antibodies to P2: An electrophysiological and immunoproteomic analysis. Muscle and Nerve, 2008, 38, 933-938.	2.2	6
69	A novel antiganglioside specificity against terminal NeuNAc(alfa 2â€“3)Gal in acute bulbar palsy. Journal of Neuroimmunology, 2006, 176, 219-222.	2.3	5
70	Absence of Dysferlin Alters Myogenin Expression and Delays Human Muscle Differentiation â€œin Vitroâ€• Journal of Biological Chemistry, 2006, 281, 17092-17098.	3.4	88
71	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	236
72	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	4